Recently, Moderna's stock price soared by more than 176% in the intraday period, and its market capitalization exceeded 69.6 billion US dollars, driving MSD to rise by more than 12%. What sparked capital demand was the positive results of the phase III Interpath-001 test jointly announced by Moderna and MSD — an individualized mRNA novel antigen vaccine combined with Keytruda, which significantly reduced the risk of recurrence and distant metastasis in melanoma patients.

Recently, Moderna's stock price soared by more than 176% in the intraday period, and its market capitalization exceeded 69.6 billion US dollars, driving MSD to rise by more than 12%. What sparked capital demand was the positive results of the phase III Interpath-001 test jointly announced by Moderna and MSD — an individualized mRNA novel antigen vaccine combined with Keytruda, which significantly reduced the risk of recurrence and distant metastasis in melanoma patients.